DENTSPLY SIRONA Inc

DENTSPLY SIRONA Inc(XRAY)股票分析

$8.440

-0.064 (-0.76%)收盤時

Loading chart…
最高
8.575
開盤
8.420
成交量加權均價
8.45
成交量
3.97M
市值
5.25B
最低
8.325
成交金額
33.52M
企業價值/稅息折舊攤銷前利潤(TTM)
5.52

DENTSPLY SIRONA Inc. is a diversified manufacturer of professional dental products and technologies. It develops, manufactures, and markets comprehensive solutions offering dental and oral health products, as well as other consumable medical devices. Its Connected Technology Solutions segment includes the design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and digital orthodontic solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for both urinary and bowel management.

AI 分析 of DENTSPLY SIRONA Inc (XRAY)

持有

DENTSPLY SIRONA Inc (XRAY) is currently trading at $8.83, which is below the average analyst price target of $12. However, the stock has experienced a significant decline of 27.68% over the past year, indicating potential ongoing challenges. The RSI is at 44.98, suggesting it is nearing oversold territory, but not quite there yet. While the company has shown some improvement in gross margin to 54.90% in Q2 2026, the forward P/E ratio is 6.33, indicating it may be undervalued. The main risk is the ongoing revenue decline, which was reported at $898 million for Q2 2026, a 4.1% decrease year-over-year, reflecting challenges in market demand.

分析師評級(13)

上檔空間 +54.50%
買進
8 買進
4 持有
1 賣出
目前: 8.44
最低
12.00
平均
13.04
最高
17.00

Piper Sandler

2026-10-09

目標價

$12

中性

BMO Capital

2026-09-17

目標價

$10

Market Perform

Barclays

2026-08-24

目標價

$11

減持

Barrington

2026-08-10

目標價

$15

優於大盤

BMO Capital

2026-08-07

目標價

$13

Market Perform

估值指標

DENTSPLY SIRONA Inc(XRAY)目前預期本益比為 6.33,5 年平均預期本益比為 13.80。

預期本益比

低估
5 年均值 P/E
13.80
目前P/E
6.33
高估
19.29
低估
8.30

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
5.06
目前EV/EBITDA
5.52
高估
31.44
低估
-21.32

預期股價營收比

低估
5 年均值 P/S
1.49
目前P/S
0.47
高估
2.20
低估
0.79

Alphio AI 對 XRAY 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%XRAY

$17.73

情境價格

基

基準

基準 · 50%XRAY

$16.62

情境價格

悲

悲觀

悲觀 · 25%XRAY

$14.22

情境價格

持有 XRAY 的大戶

E

Edmond de Rothschild Asset Management (France)

+ 持有XRAY

+8.72%

3個月報酬率

S

Southpoint Capital Advisors LP

+ 持有XRAY

+3.00%

3個月報酬率

C

Cooke & Bieler, L.P.

+ 持有XRAY

-5.45%

3個月報酬率

A

Ariel Investments, LLC

+ 持有XRAY

-5.64%

3個月報酬率

A

Armistice Capital LLC

+ 持有XRAY

-7.87%

3個月報酬率

事件時間軸

2026-08-06 (ET)

16:30:00

Company Maintains FY26 Revenue Outlook of $3.5B-$3.6B

2026-07-28 (ET)

09:30:00

Dentsply Sirona Expands Partnership with Medline Sinclair

2026-06-11 (ET)

09:30:00

Dentsply Sirona Appoints John Fortson as CFO

2026-05-05 (ET)

16:20:00

Company Maintains FY26 Revenue Outlook of $3.5B-$3.6B

16:20:00

Dentsply Sirona Reports Q1 Revenue of $880M

資訊

XRAY 常見問題 —— 由 Alphio AI 解答

DENTSPLY SIRONA Inc. is a diversified manufacturer of professional dental products and technologies. It develops, manufactures, and markets comprehensive solutions offering dental and oral health products, as well as other consumable medical devices. Its Connected Technology Solutions segment includes the design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and digital orthodontic solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for both urinary and bowel management. It operates in the Healthcare sector (DENTAL EQUIPMENT & SUPPLIES industry).

DENTSPLY SIRONA Inc (XRAY) is currently trading at $8.83, which is below the average analyst price target of $12. However, the stock has experienced a significant decline of 27.68% over the past year, indicating potential ongoing challenges. The RSI is at 44.98, suggesting it is nearing oversold territory, but not quite there yet. While the company has shown some improvement in gross margin to 54.90% in Q2 2026, the forward P/E ratio is 6.33, indicating it may be undervalued. The main risk is the ongoing revenue decline, which was reported at $898 million for Q2 2026, a 4.1% decrease year-over-year, reflecting challenges in market demand.

13 analysts cover XRAY: 8 rate it Buy, 4 Hold and 1 Sell. The average price target is 13.04.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易